tradingkey.logo

Invivyd rises after unveiling promising new antibody for children

ReutersNov 24, 2025 12:50 PM

Shares of drugmaker Invivyd IVVD.O rise 2% to $2.55 premarket

Company says it identifies a new antibody, VBY329, designed to prevent respiratory syncytial virus or RSV infections in newborns, infants and children

RSV is a virus that can cause serious lung infections in infants

Lab tests show VBY329 works better than company's current medicines nirsevimab and clesrovimab - IVVD

It also fights RSV strains that no longer respond to nirsevimab, company says

Drug is designed to stay longer in the body, which may give babies longer protection - IVVD

Up to last close, shares have jumped more than fivefold YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI